FDx Advisors’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-6,766
| Closed | -$424K | – | 411 |
|
|
2023
Q4 | $424K | Buy |
6,766
+438
| +7% | +$27.4K | 0.03% | 428 |
|
|
2023
Q3 | $287K | Sell |
6,328
-1,749
| -22% | -$79.3K | 0.02% | 489 |
|
|
2023
Q2 | $453K | Sell |
8,077
-130
| -2% | -$7.29K | 0.02% | 472 |
|
|
2023
Q1 | $334K | Hold |
8,207
| – | – | 0.01% | 534 |
|
|
2022
Q4 | $334K | Sell |
8,207
-1,816
| -18% | -$73.9K | 0.01% | 534 |
|
|
2022
Q3 | $655K | Sell |
10,023
-472
| -4% | -$30.8K | 0.03% | 360 |
|
|
2022
Q2 | $638K | Buy |
10,495
+1,897
| +22% | +$115K | 0.02% | 412 |
|
|
2022
Q1 | $540K | Buy |
8,598
+1,500
| +21% | +$94.2K | 0.02% | 483 |
|
|
2021
Q4 | $538K | Buy |
7,098
+1,013
| +17% | +$76.8K | 0.01% | 509 |
|
|
2021
Q3 | $681K | Buy |
6,085
+327
| +6% | +$36.6K | 0.02% | 419 |
|
|
2021
Q2 | $932K | Sell |
5,758
-1,255
| -18% | -$203K | 0.03% | 351 |
|
|
2021
Q1 | $855K | Sell |
7,013
-2,122
| -23% | -$259K | 0.03% | 330 |
|
|
2020
Q4 | $1.4M | Buy |
9,135
+240
| +3% | +$36.8K | 0.06% | 213 |
|
|
2020
Q3 | $744K | Buy |
8,895
+4,008
| +82% | +$335K | 0.03% | 286 |
|
|
2020
Q2 | $359K | Buy |
+4,887
| New | +$359K | 0.02% | 404 |
|